Oxerutins oral
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulations of oxerutins.
Drugs List
Therapeutic Indications
Uses
Chronic venous insufficiency oedema: symptomatic relief
Dosage
Adults
500mg twice daily.
Contraindications
Children under 18 years
First trimester of pregnancy
Precautions and Warnings
Breastfeeding
Second trimester of pregnancy
Third trimester of pregnancy
Advise ability to drive/operate machinery may be affected by side effects
Advise patient to consult physician if condition worsens / does not improve
Treatment of leg oedema due to hepatic, renal or cardiac disease should be directed to the underlying cause. Oxerutins is not indicated for these conditions.
Pregnancy and Lactation
Pregnancy
Oxerutins is contraindicated in the first trimester and should be used with caution in the second and third trimesters of pregnancy.
Animal studies show no increase in teratogenic or other effects to the foetus if used in the recommended dosage during pregnancy.
Lactation
Use oxerutins with caution in breastfeeding.
In animal studies traces of oxerutins and/or metabolites have been found in the breast milk but the levels are not considered to be of clinical relevance.
Side Effects
Abdominal pain
Alopecia
Anaphylactoid reaction
Arthralgia
Diarrhoea
Dizziness
Dyspepsia
Fatigue
Flatulence
Flushing
Gastro-intestinal disturbances
Headache
Hypersensitivity reactions
Photosensitivity
Pruritus
Rash
Urticaria
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: August 2016
Reference Sources
Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Accessed on 10 August 2016.
Summary of Product Characteristics: Paroven capsules. Novartis Consumer Health. Revised July 2019.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 21 August 2019
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.